Live Breaking News & Updates on ஹோலி மானிங்

Stay updated with breaking news from ஹோலி மானிங். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

10 Best Concerts of the Week: Speedealer, Robert Earl Keen, Cure for Paranoia and More

10 Best Concerts of the Week: Speedealer, Robert Earl Keen, Cure for Paranoia and More
dallasobserver.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dallasobserver.com Daily Mail and Mail on Sunday newspapers.

Fort Worth , United States , San Antonio , Haltom City , Oak Cliff , Michael Fitzpatrick , David Fletcher , Justin Pickard , Jimbo Wallace , Los Angeles , W Las Colinas , Michael Lee , Hayes Carll , Holly Manning , Tristan Marez , Robert Earl Keen , Sarah Ruth , Chris Welch , Lance Lipinsky , Fu Manchu , Jimmy Dale Richardson , Horton Heath , Slim Jim Phantom , Society Of Professional Journalist Sigma Delta Chi , Dallas Observer , Wild Detectives ,

Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma


Home / Top News / Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma
Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma
– Supplemental New Drug Application Planned for Submission in Q1 2021 –
CAMBRIDGE, Mass., Jan. 17, 2021 (GLOBE NEWSWIRE) Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today reported a full analysis of the final data, including mature overall survival (OS) results, from its global Phase 3 ClarIDHy trial of TIBSOVO ....

United Kingdom , United States , Comunidad Autonoma De Cataluna , Jessica Rennekamp , Holly Manning , Exchange Commission , European Society For Medical Oncology Congress , Corporate Communications , Agios Pharmaceuticals Inc , Supplemental New Drug Application Planned , Agios Pharmaceuticals , American Society , Updated Safety , European Society , Medical Oncology Congress , Lancet Oncology , Interval Prolongation , Prolonging Drugs , Prescribing Information , Private Securities Litigation Reform Act , ஒன்றுபட்டது கிஂக்டம் , ஒன்றுபட்டது மாநிலங்களில் , காமுனிடட தன்னாட்சி டி கடலுள் , ஜெசிகா றெண்னேகம்பி , ஹோலி மானிங் , பரிமாற்றம் தரகு ,

Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in ...


Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in .
Agios Pharmaceuticals, Inc.January 17, 2021 GMT
CAMBRIDGE, Mass., Jan. 17, 2021 (GLOBE NEWSWIRE) Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today reported a full analysis of the final data, including mature overall survival (OS) results, from its global Phase 3 ClarIDHy trial of TIBSOVO® (ivosidenib tablets) in patients with previously treated isocitrate dehydrogenase 1 (IDH1) mutated cholangiocarcinoma. Data from the study were featured in an oral presentation at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI), which is being held virtually January 15-17, 2021. ....

United Kingdom , United States , Comunidad Autonoma De Cataluna , Jessica Rennekamp , Chris Bowden , Andrew Zhu , Holly Manning , Exchange Commission , European Society For Medical Oncology Congress , Jiahui International Cancer Center , Corporate Communications , Agios Pharmaceuticals Inc , Harvard Medical School , American Society , Massachusetts General Hospital , Harvard Medical , Updated Safety , European Society , Medical Oncology Congress , Lancet Oncology , Interval Prolongation , Private Securities Litigation Reform Act , Investor Relations , Products And Services , Government Regulations , Drug Approvals ,

Agios to Focus on Developing and Commercializing Innovative Treatments for Genetically Defined Diseases and Sell Its Oncology Business to Servier for Up to $2 Billion Plus Royalties


Published: Dec 21, 2020
CAMBRIDGE, Mass., Dec. 21, 2020 (GLOBE NEWSWIRE) Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that it will move forward with a singular focus on accelerating and expanding its genetically defined disease portfolio, including the mitapivat clinical programs and a robust pipeline of therapeutic candidates, and has entered into a definitive agreement to sell its commercial, clinical and research-stage oncology portfolio to Servier, an independent global pharmaceutical company. Agios will receive a cash consideration of up to $2.0 billion, including $1.8 billion in upfront cash and $200 million in a potential future milestone payment for vorasidenib, as well as 5% royalties on U.S. net sales of TIBSOVO ....

United States , United Kingdom , Rosen Katz , Jessica Rennekamp , Olivier Laureau , Bristol Myers Squibb , Davidk Lee , Holly Manning , Jackie Fouse , Development Agreement , Us National Institutes Of Health , Servier Group , Exchange Commission , Corporate Communications , Servier Pharmaceuticals , Goldman Sachs Co , Securities Exchange , Agios Pharmaceuticals Inc , Morgan Stanley Co , Morgan Stanley , Cooperative Research , Private Securities Litigation Reform Act , Securities Act , Securities Exchange Act , Risk Factors , Annual Report ,